Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12292666 | 1.00 | MDM4 (0.50) | MDM4TP53CASP3KMT2ATLR2 | |
| SCHEMBL8227141 | 0.92 | MDM4 (0.50) | MDM4TP53CASP3KMT2ATLR2 | |
| SCHEMBL29594836 | 0.92 | MDM4 (0.50) | MDM4TP53CASP3KMT2ATLR2 | |
| SCHEMBL30625930 | 0.92 | KMT2A (0.48) | MDM4TP53CASP3KMT2A | |
| SCHEMBL118112 | 0.92 | MDM4 (0.54) | MDM4TP53CASP3KMT2ATLR2 | |
| SCHEMBL31248559 | 0.92 | MDM4 (0.54) | MDM4TP53CASP3KMT2ATLR2 | |
| SCHEMBL8227161 | 0.92 | MDM4 (0.54) | MDM4TP53CASP3KMT2ATLR2 | |
| SCHEMBL29362168 | 0.92 | MDM4 (0.54) | MDM4TP53CASP3KMT2ATLR2 | |
| SCHEMBL29352034 | 0.92 | MDM4 (0.54) | MDM4TP53CASP3KMT2ATLR2 | |
| SCHEMBL15521126 | 0.92 | MDM4 (0.54) | MDM4TP53CASP3KMT2ATLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335726-B2 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | CUBIST PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20060223983-A1 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | CUBIST PHARMACEUTICALS, INC. | 2006-10-05 | — | — | US | disclosed |
| WO-2003017924-A2 | LIPOPEPTIDE STEREOISOMERS, METHODS FOR PREPARING SAME, AND USEFUL INTERMEDIATES | CUBIST PHARMACEUTICALS, INC. (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223983-A1 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | NGLY1, LSS, NRDC | MDM4 2534/4885TP53 3035/4885CASP3 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.